Navigation Links
18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
Date:7/15/2008

rium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products. For additional information, please visit http://www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential failure of Zevalin to prove safe and effective for treatment of non-Hodgkin's lymphoma, determinations by regulatory, pate
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
3. Sysmex America Awarded MedAssets Supply Chain Systems Hematology Contract Extension
4. AMDL Announces Filing of Extension on Third Quarter 2007 Form 10-QSB
5. Sinovac Requests Extension for Annual Shareholders Meeting
6. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
7. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
8. Resverlogix Share Option Extension
9. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
10. SENOMYX ANNOUNCES EXTENSION OF DISCOVERY AND DEVELOPMENT COLLABORATION WITH CADBURY PLC
11. Campbell Alliance Managed Markets Practice to Take Leadership Role at CBIs Formulary and Reimbursement Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... LOS ANGELES , July 23, 2014 /PRNewswire-iReach/ -- ... enhance cognitive performance for the long term. They are ... competitive edge of sustained energy as an alternative to ... launch Think Drinks on Indiegogo on July 29, 2014, ... the 30-day campaign. Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)... DENVER , July 23, 2014  Having the ... making is vital to accelerating business growth and achieving ... American Hospital Association (AHA) Leadership Summit, July 20-22, 2014, ... prestigious panel of hospital executives and healthcare experts discussing ... Joanne Carrocino , President & Chief Executive Officer ...
(Date:7/23/2014)... 23, 2014 DuPont Pioneer announced today ... vice president of Agricultural Biotechnology (ABT), effective July 21, ... served most recently as president, chief executive officer and ... leadership in the seed and crop protection industry to ... E. Schickler , president of DuPont Pioneer. “I am ...
(Date:7/23/2014)... July 23, 2014  GrowBLOX Sciences, Inc. (OTCQB: GBLX), a ... is filing for two medical marijuana dispensary locations in ... addition to the Clark County, Nevada ... permit, as previously announced.  GrowBLOX Sciences, CEO ... two new applications for dispensaries in the City ...
Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3
... TAIAN CITY, China, July 16 /PRNewswire-Asia-FirstCall/ -- China Biologic,Products, ... "Company"),one of the leading plasma-based pharmaceutical companies in the ... hosted a forum of,industry experts on July 10 - ... discuss future development strategies for the Company. , ...
... , , , ... announced today that it had closed its series A financing round. The infusion ... of technology that converts a wide variety of cellulosic materials (such as algae, ... , As part of the agreement, the lead investor ...
... , HALIFAX, July 15 /PRNewswire/ - Scientists in Atlantic Canada ... skin aging. Researchers were investigating the genetic cause of a ... causes skin on the hands, feet and face to be ... delays including effects on the brain. In the process, researchers ...
Cached Biology Technology:China Biologic Products Hosts its First Forum for Strategy and Development 2China Biologic Products Hosts its First Forum for Strategy and Development 3Canadian researchers discover gene related to the appearance of aging 2
(Date:7/23/2014)... by satellite over a 15-year period off the U.S. ... feed in specific locations each year, according to a ... PLOS ONE by Ladd Irvine from Oregon ... to mitigate human threats to the whale population. , ... recover since the establishment of protections in the mid-1960s. ...
(Date:7/23/2014)... experiments using tissue samples cultured from cystic fibrosis patients, ... UNC Marsico Lung Institute have shown that a new ... another CF drug. , The finding, published today in ... a mutant CFTR protein becomes unstable and loses its ... the two drugs. The research offers several insights into ...
(Date:7/23/2014)... , , , , , , , , ... , , , , , ... researchers are proposing that changing how medical care is delivered could help prevent multiple chronic diseases and extend healthy lifespan. The idea, they argue, would be ... , , , , , ... , , , , , ...
Breaking Biology News(10 mins):Blue whales' dangerous feeding grounds 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5
... gets his new laser laboratory operational later this year, ... to pluck molecular bonds like a stringed musical instrument. ... of Chemistry, arrived at the University of Chicago in ... aid of ultrafast vibrational spectroscopy methods that he has ...
... maxillary sinuses. Those bulbous pouches on either side of the ... sinus infections than anything else. They were thought to be ... present value. Yet researchers led by the University of ... role in the shape and function of the human nose, ...
... March 12, 2013  Spiral Genetics, a cloud-based big data ... A financing, led by venture capital firm DFJ.  The ... create revolutionary tools that empower the bioinformatics community to ... company intends to use the funds to expand its ...
Cached Biology News:Watery research theme to flow through new Tokmakoff lab 2Watery research theme to flow through new Tokmakoff lab 3The nose's unheralded neighbor 2The nose's unheralded neighbor 3Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia 2Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia 3
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
...
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
Biology Products: